Prev Close | 1.24 |
Open | 1.23 |
Day Low/High | 1.16 / 1.32 |
52 Wk Low/High | 0.27 / 2.34 |
Volume | 6.73M |
Prev Close | 1.24 |
Open | 1.23 |
Day Low/High | 1.16 / 1.32 |
52 Wk Low/High | 0.27 / 2.34 |
Volume | 6.73M |
Exchange | NASDAQ |
Shares Outstanding | 134.20B |
Market Cap | 181.17M |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
Markets have turn flat over the past hour almost like investors just want a long week to be over. Facebook discloses that it discovered a security vulnerability that affected nearly 50 million accounts. The stock is down more than 3% on this latest ...
Here are two I think will bounce back before the end of the year.
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
The first part of Flexion's decline can be attributed to some profit taking.
Flexion Therapeutics and Adamis Pharmaceuticals are names to like at current levels.
Several firms hiked price targets on Portola into the $70s this week.
Several firms hiked price targets on Portola into the $70s this week.
Looks like the grocery sector is going to be a theme for this Friday. In the story of the day, and maybe of the week, Amazon has announced it will buy organic food pioneer Whole Foods for $42 a share in an all-cash transaction. Walmart is down 5% i...
As always, I am happy to stand in today for Doug Kass here at the Daily Diary. We already are at the midway point of June and coming up on the end of the first half of the year as well. The markets have provided solid returns to this point. although...
But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.
But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.
The EpiPen controversy makes this stock a shot in the dark.
Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.